← Leaderboards
Wei Li
Tufts Medical Center
$15,618,115
Attributed
$19,010,720
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,010,720 · 14
By mechanism
R24$7,644,802 · 1
R01$6,961,687 · 5
R44$1,963,529 · 1
R21$1,273,120 · 3
R43$481,582 · 2
R03$461,000 · 1
Top collaborators
- Hong Tian5 shared
- Keith A Webster5 shared
- Zheng Jiang1 shared
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessAngiogenic FactorNovel TherapeuticsVascular Endothelial Growth FactorsAngiogenesisSecretogranin IiiAnimal ModelAngiogenesis InhibitorsBindingLigandsMonoclonal AntibodiesPharmacotherapyBlood VesselsPathologicAntibodiesProteinsRanibizumabVascular DiseasesVisionRetinaSafetyInnovationNeutralizing Monoclonal AntibodiesRetinopathy Of Prematurity
Grant awards (40)
Developing a novel therapy for diabetic retinopathy$981,661
R44 · FY2025 · EY
Paradoxical role of anti-VEGF therapy in subretinal fibrosis of wet AMD$670,496
R01 · FY2025 · EY · contact PI
The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential$568,122
R01 · FY2025 · EY · contact PI
Developing a novel therapy for diabetic retinopathy$981,868
R44 · FY2024 · EY
Paradoxical role of anti-VEGF therapy in subretinal fibrosis of wet AMD$670,496
R01 · FY2024 · EY · contact PI
Developing a novel disease-targeted anti-angiogenic therapy for CNV$440,000
R21 · FY2023 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$1
R24 · FY2023 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$2,080,258
R24 · FY2022 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$388,001
R01 · FY2022 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$250,960
R01 · FY2022 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$76,000
R24 · FY2022 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$2,092,566
R24 · FY2021 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$388,002
R01 · FY2021 · EY · contact PI
A new drug entity for combination therapy of diabetic retinopathy$256,582
R43 · FY2021 · EY
A selective angiogenesis blocker to treat retinopathy of prematurity$1,838,570
R24 · FY2020 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$327,303
R01 · FY2020 · EY · contact PI
Anti-angiogenic gene therapy of ocular vascular diseases$225,000
R43 · FY2020 · EY
A Diabetic Retinopathy-Associated Vascular Permeability Factor$56,447
R01 · FY2020 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$1,360,447
R24 · FY2019 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$383,750
R01 · FY2019 · EY · contact PI
A selective angiogenesis blocker to treat retinopathy of prematurity$196,960
R24 · FY2019 · EY · contact PI
A Diabetic Retinopathy-Associated Vascular Permeability Factor$383,750
R01 · FY2018 · EY · contact PI
A disease-specific retinal angiogenic factor and its receptor$230,250
R21 · FY2017 · EY · contact PI
Developing a novel therapy for diabetic retinopathy$225,000
R41 · FY2017 · EY · contact PI
A disease-specific retinal angiogenic factor and its receptor$191,875
R21 · FY2016 · EY · contact PI
Elucidation of Tubby and Tulp 1 Mechanisms by Comparitive Functional Proteomics$261,854
R01 · FY2014 · GM · contact PI
Elucidation of Tubby and Tulp 1 Mechanisms by Comparitive Functional Proteomics$256,060
R01 · FY2013 · GM · contact PI
Unraveling the Mystery of Molecular Phagocyte Biology for Microglia$181,495
R21 · FY2013 · HD · contact PI
Elucidation of Tubby and Tulp 1 Mechanisms by Comparitive Functional Proteomics$266,794
R01 · FY2012 · GM · contact PI
Unraveling the Mystery of Molecular Phagocyte Biology for Microglia$229,500
R21 · FY2012 · HD · contact PI
Elucidation of Tubby and Tulp 1 Mechanisms by Comparitive Functional Proteomics$266,625
R01 · FY2011 · GM · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$145,474
R01 · FY2010 · EY · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$331,002
R01 · FY2009 · EY · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$324,383
R01 · FY2008 · EY · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$331,002
R01 · FY2007 · EY · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$332,865
R01 · FY2006 · EY · contact PI
PROFILING AUTOANTIGENS IN UVEITIS$358,301
R01 · FY2005 · EY
Modulation of CD4+ T cells in autoimmune uveitis$151,500
R03 · FY2003 · EY
Modulation of CD4+ T cells in autoimmune uveitis$151,500
R03 · FY2002 · EY
Modulation of CD4+ T cells in autoimmune uveitis$158,000
R03 · FY2001 · EY